Sodium glycerophosphate in the treatment of neonatal hypophosphataemia

I Costello, C Powell, A F Williams

Abstract

Nineteen very low birthweight (mean (SD) gestational age 28 (3) weeks) were parenterally fed nutrition solutions containing inorganic calcium and phosphorus salts. All infants had hypophosphataemia. Plasma concentrations were maintained between 1·5 mmol/l and 2·2 mmol/l. Plasma phosphorus concentrations reached 1·5 mmol/l or greater in three patients after 12 hours, in a further nine patients after 36 hours, and in all patients by 60 hours. Changes in plasma calcium concentrations were not significant.

(Arch Dis Child 1995; 73: F44–F45)

Keywords: sodium glycerophosphate, hypophosphataemia.

The provision of calcium and phosphorus in parenteral nutrition solutions is limited by the low solubility of inorganic calcium and phosphorus salts. Hypophosphataemia in parenterally fed very low birthweight infants is therefore difficult to treat.1 The use of an organic phosphate salt, such as sodium glycerophosphate, allows higher concentrations of calcium and phosphorus to remain in solution without reducing solution pH.2–5 Phosphorus in the form of a metabolisable anion also reduces the contribution made by inorganic phosphorus salts to the net acid concentration of parenteral nutrition regimens.

Method

The mean (SD) gestational age was 28 (3) weeks. The median birthweight was 0·8 kg (range 0·65–2·2 kg). The mean postnatal age at onset of hypophosphataemia was 6 (2) days.

Nineteen parenterally fed very low birthweight infants with hypophosphataemia (defined as a plasma phosphorus concentration of less than 0·5 mmol/l) were studied while all were receiving parenteral nutrition solutions containing inorganic calcium and phosphorus salts at the limits of solubility.

Plasma calcium and inorganic phosphorus concentrations were routinely measured each day in infants receiving parenteral nutrition. If the plasma phosphorus concentration fell below 0·5 mmol/l, sodium glycerophosphate was used as the sole phosphorus source to increase the amount of phosphorus provided in the parenteral nutrition solutions from 0·5–1·0 mmol/kg/day to 1·5 mmol/kg/day infused over 24 hours. This also permitted an increase in the amount of calcium infused to 1·5 mmol/kg/day, supplied as calcium gluconate.

Infants continued to receive the increased amounts of calcium and phosphorus. Plasma concentrations were maintained between 1·5 mmol/l and 2·2 mmol/l.

Sodium glycerophosphate is supplied as a solution for injection containing 2 mmol/ml sodium and 1 mmol/ml of phosphorus (Kabi-Pharmacia).

Routine plasma samples were timed as closely as possible to 12, 36, and 60 hours after the addition of the glycerophosphate parenteral nutrition solutions. Calcium and phosphorus concentration were analysed using the phosphate–molybdate complex method for ionised phosphate (PO₄³⁻) and the cresolphthalein complexone method for calcium. These methods are used in most hospital biochemistry laboratories for routine measurement of plasma calcium and phosphorus concentrations. Standard solutions of sodium glycerophosphate and parenteral nutrition containing glycerophosphate were also analysed to exclude interference with the assay procedure for plasma inorganic phosphate.

The standard solutions of glycerophosphate did not interfere with the assay procedure for inorganic plasma phosphate, indicating that all measured plasma phosphate was inorganic.

STATISTICAL ANALYSIS

The paired two tailed Student’s t test was used to determine the significance of differences in the mean plasma concentrations of calcium and phosphate before and during the infusion of sodium glycerophosphate.
Sodium glycerophosphate in the treatment of neonatal hypophosphataemia

Results
The mean (SD) increases in plasma phosphorus concentration from baseline at 12, 36, and 60 hours after initiation of glycerophosphate supplemented parenteral nutrition were 0·33 (0·08), 0·72 (0·3), and 0·90 (0·3) mmol/l, respectively; P<0·0001 (figure).

The corresponding changes in plasma calcium concentration were 0·02 (0·22) mmol, −0·23 (0·23) mmol, and −0·17 (0·26) mmol, respectively. These changes were not significant.

Plasma phosphorus concentrations reached 1·5 mmol/l or greater in three patients after 12 hours, in a further nine patients after 36 hours, and in all patients by 60 hours. No adverse effects were noted.

Discussion
Use of sodium glycerophosphate allowed greater concentrations of calcium and phosphorus to be administered via parenteral nutrition solutions. This uncontrolled study indicated that administration of phosphorus as sodium glycerophosphate (1·5 mmol/kg/day) was associated with a significant increase in plasma phosphorus concentrations.

The mechanism of the observed effect on plasma phosphate is unclear. Either phosphate from infused glycerophosphate is directly available or phosphorus is displaced from the intracellular phosphate pool.

Glycerophosphate is metabolised by plasma alkaline phosphatase, releasing phosphate and glycerol. As alkaline phosphatase is present and active in neonatal plasma, we propose that phosphate is derived from the glycerophosphate molecule itself. Glycerol is presumably rephosphorylated in the liver by glycerol kinase and utilised in glycolytic or gluconeogenic pathways.

Hanning et al.6 have shown that conventional doses of organic and inorganic calcium and phosphorus salts in parenteral nutrition solutions achieve similar mineral retention rates in neonates, but further work is required to determine the effects of delivering increased amounts of phosphorus as sodium glycerophosphate, such as those used in our study, on bone mineral accretion.

Sodium glycerophosphate in the treatment of neonatal hypophosphataemia.

I. Costello, C. Powell and A. F. Williams

Arch Dis Child Fetal Neonatal Ed 1995 73: F44-F45
doi: 10.1136/fn.73.1.F44

Updated information and services can be found at:
http://fn.bmj.com/content/73/1/F44

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/